Tag: biosimilars market demand

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Key Milestones in the Biosimilars Market’s Growth Trajectory From 2025 To 2034?

In recent times, the biosimilars market has seen a sharp increase in size. The market value, which is predicted to shift from $18.65 billion in 2024 to $21.85 billion in 2025, will exhibit a compound annual growth rate (CAGR) of 17.2%. This notable growth in the historical period is due to various factors, namely, a rise in cancer cases, significant economic development in budding markets, an escalade in the expenditure for pharmaceutical R&D, expanded healthcare funding, increasing governmental initiatives, a robust drug pipeline, diminutive cost of biosimilars, and a surge in patent expirations.

The biosimilars market is projected to experience rapid expansion in the coming years, escalating to $41.34 billion in 2029 with a compound annual growth rate (CAGR) of 17.3%. Various factors contributing to this anticipated growth in the forecast period include the rising incidence of cancer, escalating demand for prophylaxis with granulocyte colony-stimulating factor (G-CSF), growth in healthcare spending, increased potential in upcoming economies, advances in technology, the growing influence of biological drugs, the aging demographic, and enhanced healthcare access. In the forecast period, significant trends include heightened emphasis on rigorous R&D for the creation of innovative and potent drugs, a focus on mergers and acquisitions as a growth plan, efforts towards forming strategic alliances, increased investment, and a shift towards integrating artificial intelligence.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2807&type=smp

What Are the Core Market Drivers Propelling Growth in the Biosimilars Industry?

The escalating prevalence of chronic illnesses such as arthritis, asthma, and cancer is anticipated to be a primary driving force for the biosimilars market. Factors contributing to the rise in chronic diseases include extended work hours, limited physical exercise, along with unhealthy dietary and drinking choices, and biosimilars are increasingly becoming a common treatment method for such diseases. They work by initiating the immune system’s response against cancer cells, assisting the body in eradicating the cancer cells. A United Nations piece suggests that by 2030, chronic diseases are expected to cause 70% of all global deaths. Furthermore, the worldwide impact of chronic disease is predicted to reach approximately 60%. Hence, the upward trend in chronic diseases is likely to fuel the demand for biosimilars, subsequently advancing the biosimilars market.

How Is the Biosimilars Market Segmented?

The biosimilars market covered in this report is segmented –

1) By Type: Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Other Hormones, Others

2) By Product: Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins

3) By Application: Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Other Applications

Subsegments:

1) By Monoclonal Antibodies: IgG Biosimilars, Non-IgG Biosimilars

2) By Insulin: Rapid-Acting Insulin Biosimilars, Long-Acting Insulin Biosimilars, Premixed Insulin Biosimilars

3) By Erythropoietin: Epoetin Alfa Biosimilars, Darbepoetin Alfa Biosimilars

4) By Granulocyte-Colony Stimulating Factor (G-CSF): Filgrastim Biosimilars, Pegfilgrastim Biosimilars

5) By Other Hormones: Growth Hormones, Hormonal Replacement Therapy Biosimilars

6) By Others: Enzyme Biosimilars, Vaccines, Other Biologics

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=2807&type=smp

Which Regions Are Driving the Next Phase of the Biosimilars Market Growth?

North America was the largest region in the global biosimilars market in 2024. Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Key Market Trends and Innovations Are Shaping the Future of the Biosimilars Industry?

In an effort to establish a competitive presence in the biosimilars market, leading companies are centred on the creation of novel products. More than a million patients with certain severe inflammatory illnesses rely on Humira, and AMJEVITA is the first biosimilar to this medication in the U.S. For instance, Amgen Inc., a biotechnology company based in the U.S., introduced AMJEVITA (adalimumab-atto), a biosimilar to Humira (adalimumab), in the U.S. in January 2023. AMJEVITA (40 mg) is been offered at a wholesale acquisition cost, which is 55% lower than the existing Humira’s list price. It’s also provided with a 5% reduction on the existing list price of Humira.

View the full report here:

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

How Is the Biosimilars Market Defined and What Are Its Core Parameters?

Biosimilars are medications made from living things, though they can be made in a variety of ways and with slightly different materials. Due to the intricacy and high cost of their creation, as well as their molecular size and structure, biosimilars are fundamentally distinct from generic drugs.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2807

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#What Are the Key Milestones in the Biosimilars Market’s Growth Trajectory From 2025 To 2034?#_x000D_

In recent times, the biosimilars market has seen a sharp increase in size. The market value, which is predicted to shift from $18.65 billion in 2024 to $21.85 billion in 2025, will exhibit a compound annual growth rate (CAGR) of 17.2%. This notable growth in the historical period is due to various factors, namely, a rise in cancer cases, significant economic development in budding markets, an escalade in the expenditure for pharmaceutical R&D, expanded healthcare funding, increasing governmental initiatives, a robust drug pipeline, diminutive cost of biosimilars, and a surge in patent expirations._x000D_

_x000D_

The biosimilars market is projected to experience rapid expansion in the coming years, escalating to $41.34 billion in 2029 with a compound annual growth rate (CAGR) of 17.3%. Various factors contributing to this anticipated growth in the forecast period include the rising incidence of cancer, escalating demand for prophylaxis with granulocyte colony-stimulating factor (G-CSF), growth in healthcare spending, increased potential in upcoming economies, advances in technology, the growing influence of biological drugs, the aging demographic, and enhanced healthcare access. In the forecast period, significant trends include heightened emphasis on rigorous R&D for the creation of innovative and potent drugs, a focus on mergers and acquisitions as a growth plan, efforts towards forming strategic alliances, increased investment, and a shift towards integrating artificial intelligence._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=2807&type=smp_x000D_

_x000D_

#What Are the Core Market Drivers Propelling Growth in the Biosimilars Industry?#_x000D_

The escalating prevalence of chronic illnesses such as arthritis, asthma, and cancer is anticipated to be a primary driving force for the biosimilars market. Factors contributing to the rise in chronic diseases include extended work hours, limited physical exercise, along with unhealthy dietary and drinking choices, and biosimilars are increasingly becoming a common treatment method for such diseases. They work by initiating the immune system’s response against cancer cells, assisting the body in eradicating the cancer cells. A United Nations piece suggests that by 2030, chronic diseases are expected to cause 70% of all global deaths. Furthermore, the worldwide impact of chronic disease is predicted to reach approximately 60%. Hence, the upward trend in chronic diseases is likely to fuel the demand for biosimilars, subsequently advancing the biosimilars market._x000D_

_x000D_

#How Is the Biosimilars Market Segmented?#_x000D_

The biosimilars market covered in this report is segmented – _x000D_

_x000D_

1) By Type: Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Other Hormones, Others_x000D_

2) By Product: Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins _x000D_

3) By Application: Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Other Applications_x000D_

_x000D_

Subsegments:_x000D_

1) By Monoclonal Antibodies: IgG Biosimilars, Non-IgG Biosimilars _x000D_

2) By Insulin: Rapid-Acting Insulin Biosimilars, Long-Acting Insulin Biosimilars, Premixed Insulin Biosimilars _x000D_

3) By Erythropoietin: Epoetin Alfa Biosimilars, Darbepoetin Alfa Biosimilars _x000D_

4) By Granulocyte-Colony Stimulating Factor (G-CSF): Filgrastim Biosimilars, Pegfilgrastim Biosimilars _x000D_

5) By Other Hormones: Growth Hormones, Hormonal Replacement Therapy Biosimilars _x000D_

6) By Others: Enzyme Biosimilars, Vaccines, Other Biologics _x000D_

_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=2807&type=smp_x000D_

_x000D_

#Which Regions Are Driving the Next Phase of the Biosimilars Market Growth?#_x000D_

North America was the largest region in the global biosimilars market in 2024. Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa_x000D_

_x000D_

#What Key Market Trends and Innovations Are Shaping the Future of the Biosimilars Industry?#_x000D_

In an effort to establish a competitive presence in the biosimilars market, leading companies are centred on the creation of novel products. More than a million patients with certain severe inflammatory illnesses rely on Humira, and AMJEVITA is the first biosimilar to this medication in the U.S. For instance, Amgen Inc., a biotechnology company based in the U.S., introduced AMJEVITA (adalimumab-atto), a biosimilar to Humira (adalimumab), in the U.S. in January 2023. AMJEVITA (40 mg) is been offered at a wholesale acquisition cost, which is 55% lower than the existing Humira’s list price. It’s also provided with a 5% reduction on the existing list price of Humira._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report_x000D_

_x000D_

#How Is the Biosimilars Market Defined and What Are Its Core Parameters?#_x000D_

Biosimilars are medications made from living things, though they can be made in a variety of ways and with slightly different materials. Due to the intricacy and high cost of their creation, as well as their molecular size and structure, biosimilars are fundamentally distinct from generic drugs._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2807_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Europe +44 7882 955267_x000D_

Asia & Others +44 7882 955267 & +91 8897263534_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#What Is the Forecast for the Biosimilars Market from 2024 to 2025?#_x000D_

Over the past several years, the biosimilars market has experienced a significant surge. The market value is expected to rise from $18.65 billion in 2024 to $21.95 billion in 2025, equating to a compound annual growth rate (CAGR) of 17.7%. The remarkable expansion during the historical period can be attributed to factors such as the increased incidences of cancer, robust economic development in emerging markets, a hike in R&D spending in the pharmaceutical sector, increased healthcare expenditure, expanded government initiatives, a robust lineup of pharmaceutical products in the pipeline, reasonable pricing of biosimilars and an escalation in patent expirations._x000D_

_x000D_

#What Is the Projected Market Size of the Biosimilars Market?#_x000D_

The biosimilars market is poised to experience significant expansion in the coming years, ballooning to the tune of $42.16 billion by 2029, and at a compound annual growth rate (CAGR) of 17.7%. This predicted growth within the projection period can be credited to a combination of factors such as the rising occurrence of cancer, growing need for prophylaxis with granulocyte colony-stimulating factor (G-CSF), an upsurge in healthcare expenditure, the high promise of up-and-coming economies, advancements in technology, prevalent use of biological drugs, an ageing demographic, and enhanced access to healthcare. Key trends for this forecast period encompass an emphasis on vigorous R&D activities aimed at crafting effective and cutting-edge drugs, a focus on mergers and acquisitions growth strategies, establishing strategic alliances, ramping up investments, and leveraging artificial intelligence._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=2807&type=smp_x000D_

_x000D_

#Who are the Major Competitors in the Biosimilars Market Outlook?#_x000D_

Major companies operating in the biosimilars market include Amgen, Novartis AG, Samsung Bioepis Co., Ltd., Viatris, Celltrion, Inc., Coherus Biosciences, Eli Lilly and Company, Dr. Reddy’s Laboratories, Roche India Pvt Ltd, Abbott India Limited, bioMérieux India, Becton Dickinson Private Limited, Danaher Corporation, Wuxi biologics, shanghai Henlius biotech, Innovent Biologics, Hisun Pharma, 3SBio, Beijing ShuangLu Pharmaceuticals, Qilu Pharmaceutical, Kyowa Hakko Kirin, Takeda, Mitsubishi Tanabe, AGC Biologics, Bio-Thera, Sandoz Pty Ltd, Apotex Pty Ltd, Cadila Pharmaceuticals, BiosanaPharma, GlaxoSmithKline, AstraZeneca, Bayer, Merck, Boehringer Ingelheim, Sanofi, Fresenius Kabi, Napp Pharmaceuticals, Mundipharma Deutschland GmbH & Co. KG, Geropharm, Valenta, NovaMedica, SynBio, Rani Therapeutics, Johnson & Johnson, Biogen Inc., Aché, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Cipla Medpro South Africa, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty)_x000D_

_x000D_

#What Is Fueling Growth in the Biosimilars Market?#_x000D_

The escalating incidences of long-term illnesses such as arthritis, asthma, and cancer are predicted to serve as a significant catalyst to the biosimilars market. Extended working schedules, inadequate physical exercise, coupled with poor nutrition, and excessive consumption of alcohol and other harmful substances often lead to the surge of chronic illnesses. These diseases are increasingly managed using biosimilars. Biosimilars stimulate the reaction of the immune system against cancer cells, aiding the body in getting rid of these cells. A United Nations report forecasts that by 2030, chronic illnesses will account for 70% of global fatalities. The overall chronic disease burden is expected to hit around 60%. Consequently, the escalating incidences of chronic illnesses are anticipated to spur the demand for biosimilars, thereby fueling the growth of the biosimilars market._x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=2807&type=smp_x000D_

_x000D_

#Which Biosimilars Market Segments Are Growing the Fastest?#_x000D_

The biosimilars market covered in this report is segmented –_x000D_

_x000D_

1) By Type: Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Other Hormones, Others_x000D_

2) By Product: Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins_x000D_

3) By Application: Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Other Applications_x000D_

_x000D_

Subsegments:_x000D_

1) By Monoclonal Antibodies: IgG Biosimilars, Non-IgG Biosimilars_x000D_

2) By Insulin: Rapid-Acting Insulin Biosimilars, Long-Acting Insulin Biosimilars, Premixed Insulin Biosimilars_x000D_

3) By Erythropoietin: Epoetin Alfa Biosimilars, Darbepoetin Alfa Biosimilars_x000D_

4) By Granulocyte-Colony Stimulating Factor (G-CSF): Filgrastim Biosimilars, Pegfilgrastim Biosimilars_x000D_

5) By Other Hormones: Growth Hormones, Hormonal Replacement Therapy Biosimilars_x000D_

6) By Others: Enzyme Biosimilars, Vaccines, Other Biologics_x000D_

_x000D_

_x000D_

#Which Industry Trends Are Shaping the Future of the Biosimilars Market?#_x000D_

In an effort to establish a competitive edge in the biosimilars market, major companies are concentrating on the creation of innovative products. More than a million patients suffering from certain severe inflammatory diseases use Amgen Inc.’s AMJEVITA, a US-based biotech firm’s debut biosimilar to Humira in the United States. As of January 2023, AMJEVITA (adalimumab-atto) was launched as a biosimilar to Humira (adalimumab) and became available in the US market. The list price (wholesale procurement cost) of AMJEVITA (40 mg) is 55% lower than the current list price of Humira, and it is also available at a price 5% less than Humira’s current list price._x000D_

_x000D_

#Access The Full Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report_x000D_

_x000D_

#Which Countries Are Leading the Biosimilars Market?#_x000D_

North America was the largest region in the global biosimilars market in 2024. Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa_x000D_

_x000D_

#Purchase The Full Report Today:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2807_x000D_

_x000D_

#This Report Delivers Insight On: #_x000D_

1. How big is the biosimilars market, and how is it changing globally?_x000D_

2. Who are the major companies in the biosimilars market, and how are they performing?_x000D_

3. What are the key opportunities and risks in the biosimilars market right now?_x000D_

4. Which products or customer segments are growing the most in the biosimilars market?_x000D_

5. What factors are helping or slowing down the growth of the biosimilars market?_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 2071930708_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Major Innovations Are Driving the Accelerated Growth of the Biosimilars Market?

Expectations for the biosimilars market to grow are predominantly driven by the increasing occurrence of chronic diseases such as arthritis, asthma, and cancer. The growing number of these diseases can be attributed to long working hours, lack of physical activity, and harmful eating and drinking habits. As the frequency of these diseases increases, so does the use of biosimilars for their treatment. These treatments work by activating an immune response against cancer cells and aiding in their elimination from the body. A United Nations report predicts that by 2030, chronic diseases will account for 70% of total global deaths, with a global chronic disease burden estimated to be around 60%. Consequently, the ascending incidences of chronic diseases are expected to incite the demand for biosimilars and serve as a significant driving force for the growth of the biosimilars market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2807&type=smp

How Will the Growth Rate of theBiosimilars Market Impact Industry Trends by 2034?

The biosimilars sector has experienced significant expansion in the past few years. Its market size is predicted to increase from $18.65 billion in 2024 to $21.95 billion in 2025, presenting a compound annual growth rate (CAGR) of 17.7%. This historical growth has been driven by factors such as the rising incidence of cancer, robust economic advancement in developing markets, an upsurge in pharmaceutical research and development spending, escalated healthcare costs, increasing government initiatives, a robust pipeline of medicines, the affordability of biosimilars, and a surge in patent expirations.

In the coming years, the biosimilars market is poised for a swift expansion. It is anticipated to inflate to a value of $42.16 billion by 2029, with a compound annual growth rate (CAGR) of 17.7%. Factors contributing to this expected growth within the forecast duration encompass the rising prevalence of cancer, heightened demand for prophylaxis with granulocyte colony-stimulating factor (G-CSF), increment in healthcare spending, the untapped potential of emerging economies, advancements in technology, extensive penetration of biological drugs, the aging demographic, and heightened access to healthcare. Alongside these drivers, the prediction period will spotlight certain trends such as robust R&D endeavors to invent effective and novel drugs, a concentration on M&A growth tactics, emphasis on forging strategic alliances, an increase in investments, and the harnessing of artificial intelligence.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2807

What Are the Most Significant Market Trends Transforming theBiosimilars Market?

To remain competitive in the biosimilars market, top companies are concentrating on the creation of innovative products. AMJEVITA, the inaugural U.S. biosimilar to Humira, is a medication used by over a million patients with specific severe inflammatory diseases. Amgen Inc., a biotechnology company from the U.S., introduced AMJEVITA (adalimumab-atto), a biosimilar to Humira (adalimumab), in the American market in January 2023. AMJEVITA (40 mg) is being offered at a list price, or wholesale acquisition cost, 55% lesser than the current Humira list price, and even at 5% less than the prevailing Humira list price.

What Are the Top Market Players Propelling the Growth of theBiosimilars Industry?

Major companies operating in the biosimilars market include Amgen, Novartis AG, Samsung Bioepis Co., Ltd., Viatris, Celltrion, Inc., Coherus Biosciences, Eli Lilly and Company, Dr. Reddy’s Laboratories, Roche India Pvt Ltd, Abbott India Limited, bioMérieux India, Becton Dickinson Private Limited, Danaher Corporation, Wuxi biologics, shanghai Henlius biotech, Innovent Biologics, Hisun Pharma, 3SBio, Beijing ShuangLu Pharmaceuticals, Qilu Pharmaceutical, Kyowa Hakko Kirin, Takeda, Mitsubishi Tanabe, AGC Biologics, Bio-Thera, Sandoz Pty Ltd, Apotex Pty Ltd, Cadila Pharmaceuticals, BiosanaPharma, GlaxoSmithKline, AstraZeneca, Bayer, Merck, Boehringer Ingelheim, Sanofi, Fresenius Kabi, Napp Pharmaceuticals, Mundipharma Deutschland GmbH & Co. KG, Geropharm, Valenta, NovaMedica, SynBio, Rani Therapeutics, Johnson & Johnson, Biogen Inc., Aché, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Cipla Medpro South Africa, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty)

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Which Primary Segments of the Biosimilars Market Are Driving Growth and Industry Transformations?

The biosimilars market covered in this report is segmented –

1) By Type: Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Other Hormones, Others

2) By Product: Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins

3) By Application: Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Other Applications

Subsegments:

1) By Monoclonal Antibodies: IgG Biosimilars, Non-IgG Biosimilars

2) By Insulin: Rapid-Acting Insulin Biosimilars, Long-Acting Insulin Biosimilars, Premixed Insulin Biosimilars

3) By Erythropoietin: Epoetin Alfa Biosimilars, Darbepoetin Alfa Biosimilars

4) By Granulocyte-Colony Stimulating Factor (G-CSF): Filgrastim Biosimilars, Pegfilgrastim Biosimilars

5) By Other Hormones: Growth Hormones, Hormonal Replacement Therapy Biosimilars

6) By Others: Enzyme Biosimilars, Vaccines, Other Biologics

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=2807&type=smp

Which Regions Are Key Players in the Growth of the #What Major Innovations Are Driving the Accelerated Growth of the Biosimilars Market?# Market?

North America was the largest region in the global biosimilars market in 2024. Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Reports Similar to the Global Biosimilars Market 2025, By The Business Research Company:

Oncology Biosimilars Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

Biosimilar Hormones Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/biosimilar-hormone-global-market-report

Biosimilar Interleukins Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/biosimilar-interleukin-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What fueled the previous growth in the biosimilars market?

The size of the biosimilars market has seen rapid escalation in the past few years. It is anticipated to increase from $18.65 billion in 2024 to $21.95 billion in 2025, marking a compound annual growth rate (CAGR) of 17.7%. The heightened growth during the historic period owes much to factors such as the rising incidence of cancer, robust economic ascent in developing markets, a surge in expenditure for pharmaceutical research and development, amplified healthcare spending, expanding government initiatives, a potent drugs pipeline, reduced pricing for biosimilars, and a rise in patent expiry.

What will be the biosimilars market size in the future?

In the following years, the biosimilars market is predicted to experience swift expansion, with an estimate to reach the value of $42.16 billion in 2029, displaying a compound annual growth rate (CAGR) of 17.7%. This elevation in the projection phase can be related to factors such as the growing incidence of cancer, rising requirement for preventive measures using granulocyte colony-stimulating factor (G-CSF), elevated healthcare expenditures, promising potential of up-and-coming economies, advancements in technology, extensive adaptability of biological drugs, an ageing population and improved healthcare accessibility. Foreseen trends for the period of prediction comprise a focus on vigorous R&D undertakings for the formulation of potent and innovative drugs, emphasis on M&A for growth tactics, efforts towards establishing strategic associations, concentration on increasing investments, and the utilization of artificial intelligence.

Get your biosimilars market report here!

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

What main drivers are fueling expansion in the biosimilars market?

The escalation in the occurrence of enduring illnesses such as arthritis, cancer and asthma is anticipated to have significant influence on the biosimilars market growth. Factors like excessive work hours, inactive lifestyle, and poor dietary choices contribute to the spread of such diseases which are comprehensively treated with biosimilars. They generate an immune system response against cancer cells aiding in their eradication from the body. A United Nations document predicts that by 2030, chronic diseases will cause 70% of all deaths worldwide with the overall impact of chronic disease expected to go up to about 60%. Hence, the growing prevalence of these diseases is anticipated to heighten the biosimilars’ demand, thereby inflating the biosimilars market.

What key areas define the segmentation of the global biosimilars market?

The biosimilars market covered in this report is segmented –

1) By Type: Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Other Hormones, Others

2) By Product: Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins

3) By Application: Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Other Applications

Subsegments:

1) By Monoclonal Antibodies: IgG Biosimilars, Non-IgG Biosimilars

2) By Insulin: Rapid-Acting Insulin Biosimilars, Long-Acting Insulin Biosimilars, Premixed Insulin Biosimilars

3) By Erythropoietin: Epoetin Alfa Biosimilars, Darbepoetin Alfa Biosimilars

4) By Granulocyte-Colony Stimulating Factor (G-CSF): Filgrastim Biosimilars, Pegfilgrastim Biosimilars

5) By Other Hormones: Growth Hormones, Hormonal Replacement Therapy Biosimilars

6) By Others: Enzyme Biosimilars, Vaccines, Other Biologics

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2807&type=smp

Who are the dominant players expanding their reach in the biosimilars market?

Major companies operating in the biosimilars market include Amgen, Novartis AG, Samsung Bioepis Co., Ltd., Viatris, Celltrion, Inc., Coherus Biosciences, Eli Lilly and Company, Dr. Reddy’s Laboratories, Roche India Pvt Ltd, Abbott India Limited, bioMérieux India, Becton Dickinson Private Limited, Danaher Corporation, Wuxi biologics, shanghai Henlius biotech, Innovent Biologics, Hisun Pharma, 3SBio, Beijing ShuangLu Pharmaceuticals, Qilu Pharmaceutical, Kyowa Hakko Kirin, Takeda, Mitsubishi Tanabe, AGC Biologics, Bio-Thera, Sandoz Pty Ltd, Apotex Pty Ltd, Cadila Pharmaceuticals, BiosanaPharma, GlaxoSmithKline, AstraZeneca, Bayer, Merck, Boehringer Ingelheim, Sanofi, Fresenius Kabi, Napp Pharmaceuticals, Mundipharma Deutschland GmbH & Co. KG, Geropharm, Valenta, NovaMedica, SynBio, Rani Therapeutics, Johnson & Johnson, Biogen Inc., Aché, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Cipla Medpro South Africa, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty)

How are evolving market trends shaping biosimilars Strategies?

In a bid to secure a competitive advantage in the biosimilars market, leading companies are concentrating on the development of novel products. AMJEVITA, touted as Humira’s first U.S. biosimilar, is used by over a million patients grappling with some serious inflammatory diseases. For instance, Amgen Inc., a biotechnology corporation based in the U.S., introduced AMJEVITA (adalimumab-atto), a biosimilar to Humira (adalimumab), into the U.S. market in January 2023. The listed price (wholesale acquisition cost) of AMJEVITA (40 mg) is 55% lower than the current list price of Humira. Furthermore, AMJEVITA is also offered at a list price that is 5% less than the current list price of Humira.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2807

Which regions are emerging as leaders in the biosimilars market?

North America was the largest region in the global biosimilars market in 2024. Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Oncology Biosimilars Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

Biosimilar Hormones Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/biosimilar-hormone-global-market-report

Biosimilar Interleukins Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/biosimilar-interleukin-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: